JPH07303497A - Assay of biological component and reagent composition therefor - Google Patents
Assay of biological component and reagent composition thereforInfo
- Publication number
- JPH07303497A JPH07303497A JP6099983A JP9998394A JPH07303497A JP H07303497 A JPH07303497 A JP H07303497A JP 6099983 A JP6099983 A JP 6099983A JP 9998394 A JP9998394 A JP 9998394A JP H07303497 A JPH07303497 A JP H07303497A
- Authority
- JP
- Japan
- Prior art keywords
- oxidase
- manganese
- biological component
- measuring
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 140
- 239000000203 mixture Substances 0.000 title claims description 24
- 238000003556 assay Methods 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 59
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 42
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 42
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 34
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 34
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 33
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 23
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 23
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 23
- 150000002696 manganese Chemical class 0.000 claims abstract description 19
- 150000007524 organic acids Chemical class 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
- 239000008103 glucose Substances 0.000 claims abstract description 6
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 4
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 4
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 4
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 4
- -1 inorganic acid manganese salt Chemical class 0.000 claims abstract description 4
- 229940071125 manganese acetate Drugs 0.000 claims abstract description 4
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims abstract description 4
- 108010024957 Ascorbate Oxidase Proteins 0.000 claims description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 18
- 150000007522 mineralic acids Chemical class 0.000 claims description 16
- 108010092464 Urate Oxidase Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 11
- 229940107161 cholesterol Drugs 0.000 claims description 11
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 229940109239 creatinine Drugs 0.000 claims description 11
- 229940088598 enzyme Drugs 0.000 claims description 11
- 229940116269 uric acid Drugs 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 10
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 9
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 9
- 235000002867 manganese chloride Nutrition 0.000 claims description 9
- 239000011565 manganese chloride Substances 0.000 claims description 9
- 229940099607 manganese chloride Drugs 0.000 claims description 9
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 8
- 230000002452 interceptive effect Effects 0.000 claims description 8
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- 229940067631 phospholipid Drugs 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 6
- 108010000659 Choline oxidase Proteins 0.000 claims description 5
- 108010077078 Creatinase Proteins 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 5
- 102000011420 Phospholipase D Human genes 0.000 claims description 5
- 108090000553 Phospholipase D Proteins 0.000 claims description 5
- 108010060059 Sarcosine Oxidase Proteins 0.000 claims description 5
- 102000008118 Sarcosine oxidase Human genes 0.000 claims description 5
- 108010054790 glycerol-3-phosphate oxidase Proteins 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003624 creatine Drugs 0.000 claims description 4
- 239000006046 creatine Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- KSNGEYQWLMRSIR-UHFFFAOYSA-L 2-hydroxypropanoate;manganese(2+) Chemical compound [Mn+2].CC(O)C([O-])=O.CC(O)C([O-])=O KSNGEYQWLMRSIR-UHFFFAOYSA-L 0.000 claims description 3
- QGBLCIBATKETJC-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;manganese(2+) Chemical compound [Mn+2].O1B([O-])OB2OB([O-])OB1O2 QGBLCIBATKETJC-UHFFFAOYSA-N 0.000 claims description 3
- 108010042687 Pyruvate Oxidase Proteins 0.000 claims description 3
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 3
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 3
- RJYMRRJVDRJMJW-UHFFFAOYSA-L dibromomanganese Chemical compound Br[Mn]Br RJYMRRJVDRJMJW-UHFFFAOYSA-L 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 235000021588 free fatty acids Nutrition 0.000 claims description 3
- CPSYWNLKRDURMG-UHFFFAOYSA-L hydron;manganese(2+);phosphate Chemical compound [Mn+2].OP([O-])([O-])=O CPSYWNLKRDURMG-UHFFFAOYSA-L 0.000 claims description 3
- 229940093474 manganese carbonate Drugs 0.000 claims description 3
- 235000006748 manganese carbonate Nutrition 0.000 claims description 3
- 239000011656 manganese carbonate Substances 0.000 claims description 3
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 claims description 3
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 claims description 3
- 229940107700 pyruvic acid Drugs 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 102000004317 Lyases Human genes 0.000 claims description 2
- 108090000856 Lyases Proteins 0.000 claims description 2
- 108010035473 Palmitoyl-CoA Hydrolase Proteins 0.000 claims description 2
- 102000008172 Palmitoyl-CoA Hydrolase Human genes 0.000 claims description 2
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims description 2
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims description 2
- 102000000019 Sterol Esterase Human genes 0.000 claims description 2
- 108010055297 Sterol Esterase Proteins 0.000 claims description 2
- 108010090622 glycerol oxidase Proteins 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 claims 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 claims 1
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- ISTIEXLDUGQAAO-UHFFFAOYSA-J [Mn+4].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O Chemical compound [Mn+4].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ISTIEXLDUGQAAO-UHFFFAOYSA-J 0.000 claims 1
- NVGQLLICICOXGV-UHFFFAOYSA-N [acetyloxy-[2-(diacetyloxyamino)ethyl]amino] acetate;manganese Chemical compound [Mn].CC(=O)ON(OC(C)=O)CCN(OC(C)=O)OC(C)=O NVGQLLICICOXGV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 abstract description 50
- 210000002966 serum Anatomy 0.000 abstract description 14
- CDGBQMHYFARRCC-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 CDGBQMHYFARRCC-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000004737 colorimetric analysis Methods 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 23
- 238000005259 measurement Methods 0.000 description 19
- 235000000832 Ayote Nutrition 0.000 description 16
- 235000009854 Cucurbita moschata Nutrition 0.000 description 16
- 240000001980 Cucurbita pepo Species 0.000 description 16
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 16
- 235000015136 pumpkin Nutrition 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 11
- 101710171243 Peroxidase 10 Proteins 0.000 description 9
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007994 TES buffer Substances 0.000 description 7
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000011088 calibration curve Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000012086 standard solution Substances 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)-3,4-dihydroxy-2h-furan-5-one Chemical compound OCC(O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 102000043296 Lipoprotein lipases Human genes 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 101710181606 Glycerol kinase 1 Proteins 0.000 description 3
- 101100436871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) atp-3 gene Proteins 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 2
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 2
- ZLQNJZKBJSMXCJ-UHFFFAOYSA-N 3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 ZLQNJZKBJSMXCJ-UHFFFAOYSA-N 0.000 description 2
- STBWJPWQQLXSCK-UHFFFAOYSA-N 3-(n-ethyl-3-methoxyanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(OC)=C1 STBWJPWQQLXSCK-UHFFFAOYSA-N 0.000 description 2
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- KGFAREHEJGDILZ-UHFFFAOYSA-N n,n-diethyl-3-methoxyaniline Chemical compound CCN(CC)C1=CC=CC(OC)=C1 KGFAREHEJGDILZ-UHFFFAOYSA-N 0.000 description 2
- CIPVVROJHKLHJI-UHFFFAOYSA-N n,n-diethyl-3-methylaniline Chemical compound CCN(CC)C1=CC=CC(C)=C1 CIPVVROJHKLHJI-UHFFFAOYSA-N 0.000 description 2
- ZPEDSBOBSNNATM-UHFFFAOYSA-N n-[2-(n-ethyl-3-methylanilino)ethyl]acetamide Chemical compound CC(=O)NCCN(CC)C1=CC=CC(C)=C1 ZPEDSBOBSNNATM-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 1
- BGXNGARHYXNGPK-UHFFFAOYSA-N 2-[1-[(4-methoxyphenyl)methylsulfanyl]cyclohexyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CSC1(CC(O)=O)CCCCC1 BGXNGARHYXNGPK-UHFFFAOYSA-N 0.000 description 1
- FTFFOIWLBWQKGM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;manganese Chemical compound [Mn].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O FTFFOIWLBWQKGM-UHFFFAOYSA-N 0.000 description 1
- RXXOXPGVDNVIKC-UHFFFAOYSA-N 2-hydroxy-3-(3-methylanilino)propane-1-sulfonic acid Chemical compound CC1=CC=CC(NCC(O)CS(O)(=O)=O)=C1 RXXOXPGVDNVIKC-UHFFFAOYSA-N 0.000 description 1
- ZTQGWROHRVYSPW-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZTQGWROHRVYSPW-UHFFFAOYSA-N 0.000 description 1
- IBSUMVZKDLDAEK-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(C)=C1 IBSUMVZKDLDAEK-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010066906 Creatininase Proteins 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229940079895 copper edta Drugs 0.000 description 1
- BDXBEDXBWNPQNP-UHFFFAOYSA-L copper;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydron Chemical compound [Cu+2].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O BDXBEDXBWNPQNP-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- WHYUWYVXDNNLTR-UHFFFAOYSA-J dizinc;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Zn+2].[Zn+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O WHYUWYVXDNNLTR-UHFFFAOYSA-J 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は生体成分の測定方法及び
測定用試薬組成物に関する。さらに詳しくは、生体成分
を酸化酵素を用いて測定する方法およびその測定用試薬
組成物において、アスコルビン酸による誤差のない正確
な測定を可能とする。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for measuring biological components and a reagent composition for measurement. More specifically, the method for measuring a biological component using an oxidase and the reagent composition for the measurement enable accurate measurement without error due to ascorbic acid.
【0002】[0002]
【従来の技術】血清、尿などの生体試料中のグルコー
ス、コレステロール、尿酸などの成分の存在及びその量
の測定は、臨床検査の分野において有益な情報をもたら
す。その測定方法として、それぞれの成分に対して、高
い基質特異性を有する酵素を使用した酵素的測定方法が
急速に普及している。その中でも測定対象である生体成
分に酸化酵素を作用させ、生成する過酸化水素を測定す
る方法が多く用いられている。代表的な成分と直接作用
させる酸化酵素の組み合わせとしては、グルコースとグ
ルコースオキシダーゼ、遊離コレステロールとコレステ
ロールオキシダーゼ、尿酸とウリカーゼなどが挙げられ
る。2. Description of the Related Art The presence of components such as glucose, cholesterol and uric acid in biological samples such as serum and urine and the determination of their amounts provide useful information in the field of clinical examination. As the measuring method, an enzymatic measuring method using an enzyme having high substrate specificity for each component is rapidly prevailing. Among them, a method in which an oxidase is allowed to act on a biological component to be measured and the produced hydrogen peroxide is measured is often used. Examples of a combination of a representative component and an oxidase that directly acts on the component include glucose and glucose oxidase, free cholesterol and cholesterol oxidase, and uric acid and uricase.
【0003】また測定対象である生体成分に直接、酸化
酵素が作用できない場合は、予め生体成分にある酵素を
作用させて、酸化酵素の基質となる物質を生成させた
後、該物質に酸化酵素を作用させ、生成する過酸化水素
を測定する方法が用いられる。このような代表例として
は、中性脂肪とグリセロール−3−リン酸オキシダー
ゼ、無機リンとキサンチンオキシダーゼ、リン脂質とコ
リンオキシダーゼ、クレアチニンとザルコシンオキシダ
ーゼなどが挙げられる。When the oxidase cannot act directly on the biological component to be measured, the enzyme present in the biological component is allowed to act in advance to generate a substance serving as a substrate for the oxidase, and then the oxidase is added to the substance. Is used to measure the hydrogen peroxide produced. Examples of such representatives include neutral fat and glycerol-3-phosphate oxidase, inorganic phosphorus and xanthine oxidase, phospholipid and choline oxidase, and creatinine and sarcosine oxidase.
【0004】酸化酵素の作用により生成した過酸化水素
は公知の種々の方法で測定することができるが、最も一
般的に利用されている方法は、ペルオキシダーゼの存在
下、色原体を酸化し、4−アミノアンチピリンなどのカ
ップラーと縮合させて色素を形成させて比色定量する方
法が挙げられる。この方法に用いられる色原体として
は、フェノール、2−クロロフェノール、4−クロロフ
ェノール、2,4−ジクロロフェノールなどのフェノー
ル誘導体、もしくはアニリン、N,N−ジメチルアニリ
ン、N,N−ジエチルアニリン、N,N−ジエチル−m
−トルイジン、N,N−ジエチル−m−アニシジン、N
−エチル−N−(3−メチルフェニル)−N’−アセチ
ルエチレンジアミン、N−エチル−N−(2−ヒドロキ
シ−3−スルホプロピル)−m−アニシジン、N−エチ
ル−N−(2−ヒドロキシ−3−スルホプロピル)−m
−トルイジン、N−エチル−N−スルホプロピル−m−
トルイジン、N−エチル−N−スルホプロピル−m−ア
ニシジンなどのアニリン誘導体が挙げられる。Hydrogen peroxide produced by the action of an oxidase can be measured by various known methods. The most commonly used method is to oxidize a chromogen in the presence of peroxidase. Examples include a method in which a dye is formed by condensation with a coupler such as 4-aminoantipyrine to perform colorimetric determination. Chromogens used in this method include phenol derivatives such as phenol, 2-chlorophenol, 4-chlorophenol, and 2,4-dichlorophenol, or aniline, N, N-dimethylaniline, N, N-diethylaniline. , N, N-diethyl-m
-Toluidine, N, N-diethyl-m-anisidine, N
-Ethyl-N- (3-methylphenyl) -N'-acetylethylenediamine, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-anisidine, N-ethyl-N- (2-hydroxy- 3-sulfopropyl) -m
-Toluidine, N-ethyl-N-sulfopropyl-m-
Examples include aniline derivatives such as toluidine and N-ethyl-N-sulfopropyl-m-anisidine.
【0005】[0005]
【発明が解決しようとする課題】このような生体成分の
測定方法において、生体試料中に含まれる還元物質、特
にアスコルビン酸によって測定に負誤差を生じ、正しい
測定結果が得られないことがしばしば経験されている。
この問題を解決する手段として、アスコルビン酸オキシ
ダーゼを試薬中に共存させることにより、効率的にアス
コルビン酸を分解し、生体成分の測定への干渉を回避す
る方法が用いられている。しかしながらアスコルビン酸
オキシダーゼは溶液中では容易に失活しやすいため、試
薬保存中にアスコルビン酸の分解能が低下する欠点があ
った。アスコルビン酸の分解能の低下を防止する手段と
して、アスコルビン酸オキシダーゼに種々の安定化剤を
添加することが行われている。安定化剤の例としては、
硼酸、シュクロースなどがあげられる。しかしながら、
これらの方法によってアスコルビン酸オキシダーゼの溶
液中での安定性は改善されるが、アスコルビン酸の測定
値への干渉を完全に回避するには至らなかった。In such a method for measuring a biological component, it is often experienced that a reducing substance contained in a biological sample, particularly ascorbic acid, causes a negative error in the measurement and a correct measurement result cannot be obtained. Has been done.
As a means for solving this problem, a method has been used in which ascorbic acid oxidase is allowed to coexist in a reagent to efficiently decompose ascorbic acid and avoid interference with the measurement of biological components. However, since ascorbic acid oxidase is easily deactivated in a solution, there is a drawback that the resolution of ascorbic acid is lowered during storage of the reagent. As a means for preventing a decrease in the resolution of ascorbic acid, various stabilizers have been added to ascorbate oxidase. Examples of stabilizers include
Examples thereof include boric acid and sucrose. However,
Although these methods improved the stability of ascorbate oxidase in solution, they did not completely avoid interference with ascorbate measurements.
【0006】[0006]
【課題を解決しようとする手段】本発明者らは、上記現
状に鑑みアスコルビン酸の測定値への干渉を回避する方
法を鋭意検討した結果、アスコルビン酸オキシダーゼと
有機酸または無機酸のマンガン塩を共存させることによ
って、上記課題を解決するに至った。DISCLOSURE OF THE INVENTION The inventors of the present invention have made earnest studies on a method for avoiding interference with the measured value of ascorbic acid in view of the above-mentioned situation. As a result, ascorbic acid oxidase and a manganese salt of an organic acid or an inorganic acid are selected. By coexisting, the above-mentioned subject was solved.
【0007】すなわち本発明は試料中の生体成分または
該生体成分に由来する物質に酸化酵素を作用させ、生成
した過酸化水素を測定することにより生体成分を測定す
る方法において、アスコルビン酸オキシダーゼおよび有
機酸または無機酸のマンガン塩を作用させて、生体成分
中の妨害物質を除去することを特徴とする生体成分の測
定方法である。That is, the present invention provides a method for measuring a biological component by causing an oxidase to act on a biological component in a sample or a substance derived from the biological component, and measuring the produced hydrogen peroxide. A method for measuring a biological component, which is characterized in that a manganese salt of an acid or an inorganic acid is allowed to act to remove an interfering substance in the biological component.
【0008】また本発明は酸化酵素、ペルオキシダー
ゼ、色原体、カプラー、アスコルビン酸オキシダーゼお
よび有機酸または無機酸のマンガン塩を含むことを特徴
とする生体成分の測定用試薬組成物である。The present invention also provides a reagent composition for measuring biological components, which comprises an oxidase, a peroxidase, a chromogen, a coupler, an ascorbate oxidase and a manganese salt of an organic acid or an inorganic acid.
【0009】さらに本発明は生体成分から酸化酵素の基
質を生成する酵素、酸化酵素、ペルオキシダーゼ、色原
体、カプラー、アスコルビン酸オキシダーゼおよび有機
酸または無機酸のマンガン塩を含むことを特徴とする生
体成分の測定用試薬組成物である。Further, the present invention is characterized by containing an enzyme that produces a substrate for an oxidase from a biological component, an oxidase, a peroxidase, a chromogen, a coupler, an ascorbate oxidase, and a manganese salt of an organic acid or an inorganic acid. It is a reagent composition for measuring components.
【0010】本発明において測定する生体成分として
は、グルコース、遊離コレステロール、エステル型コレ
ステロール、中性脂肪、リン脂質、無機リン、遊離脂肪
酸、尿素窒素、ピルビン酸、クレアチン、クレアチニン
または尿酸などが挙げられる。本発明において測定しよ
うとする成分はこれらの成分に限らず、酸化酵素を作用
させて過酸化水素を生成させ、その量を測定することに
より測定可能な成分を包含する。The biological components to be measured in the present invention include glucose, free cholesterol, ester type cholesterol, neutral fat, phospholipid, inorganic phosphorus, free fatty acid, urea nitrogen, pyruvic acid, creatine, creatinine or uric acid. . The components to be measured in the present invention are not limited to these components, but include components that can be measured by causing oxidase to act to generate hydrogen peroxide and measuring the amount thereof.
【0011】本発明において測定しようとする生体成分
に由来する物質としては、中性脂肪に由来するグリセロ
ールまたはグリセロール−3−リン酸、リン脂質に由来
するコリン、クレアチン、クレアチニンに由来するザル
コシン、α−アミラーゼに由来するグルコースなどが挙
げられる。また本発明において測定しようとする成分と
しては、α−アミラーゼなどの酵素類も包含される。本
発明において測定しようとする成分は、これらの成分に
限らず、酸化酵素の基質となる物質を例えば化学反応に
よって生成するものであって、該物質に酸化酵素を作用
させて過酸化水素を生成させ、その量を測定することに
より測定可能な成分も包含する。The substances derived from biological components to be measured in the present invention include glycerol or glycerol-3-phosphate derived from neutral fat, choline derived from phospholipids, creatine, sarcosine derived from creatinine, α -Glucose derived from amylase. The components to be measured in the present invention also include enzymes such as α-amylase. The component to be measured in the present invention is not limited to these components, and it is a substance that produces a substance that serves as a substrate for an oxidase by, for example, a chemical reaction, and the oxidase acts on the substance to produce hydrogen peroxide. It also includes components that can be measured by measuring the amount thereof.
【0012】生体成分に直接作用する酸化酵素として
は、グルコースオキシダーゼ、コレステロールオキシダ
ーゼ、グリセロールオキシダーゼ、キサンチンオキシダ
ーゼ、ピルビン酸オキシダーゼ、ウリカーゼなどが挙げ
られる。Examples of oxidases that directly act on biological components include glucose oxidase, cholesterol oxidase, glycerol oxidase, xanthine oxidase, pyruvate oxidase, uricase and the like.
【0013】生体成分から酸化酵素の基質となる物質を
得る酵素としては、リポプロテインリパーゼ、グリセロ
ールキナーゼ、ホスフォリパーゼD、コレステロールエ
ステラーゼ、プリンヌクレオシドホスフォリラーゼ、ク
レアチンアミジノヒドロラーゼ、クレアチニンアミドヒ
ドロラーゼ、アシルCoAシンセターゼ、ウレアアミド
リアーゼなどが挙げられる。As an enzyme for obtaining a substance serving as a substrate for oxidase from a biological component, lipoprotein lipase, glycerol kinase, phospholipase D, cholesterol esterase, purine nucleoside phosphorylase, creatine amidinohydrolase, creatinine amide hydrolase, acyl CoA Examples include synthetase and urea amide lyase.
【0014】本発明において測定する生体成分、生体成
分から酸化酵素の基質を生成する酵素、使用する酸化酵
素をまとめると以下の通りである。The biological components to be measured in the present invention, the enzyme for producing a substrate for oxidase from the biological components, and the oxidase used are summarized below.
【0015】[0015]
【表1】 [Table 1]
【0016】本発明に使用するカプラーとしては、4−
アミノアンチピリン、3−メチル−2−ベンゾチアゾリ
ノンヒドラゾンなどが挙げられる。The couplers used in the present invention include 4-
Aminoantipyrine, 3-methyl-2-benzothiazolinone hydrazone and the like can be mentioned.
【0017】本発明に使用する色原体としては、フェノ
ール、2−クロロフェノール、4−クロロフェノール、
2,4−ジクロロフェノールなどのフェノール誘導体、
もしくはアニリン、N,N−ジメチルアニリン、N,N
−ジエチルアニリン、N,N−ジエチル−m−トルイジ
ン、N,N−ジエチル−m−アニシジン、N−エチル−
N−(3−メチルフェニル)−N’−アセチルエチレン
ジアミン、N−エチル−N−(2−ヒドロキシ−3−ス
ルホプロピル)−m−アニシジン、N−エチル−N−
(2−ヒドロキシ−3−スルホプロピル)−m−トルイ
ジン、N−エチル−N−スルホプロピル−m−トルイジ
ン、N−エチル−N−スルホプロピル−m−アニシジン
などのアニリン誘導体などが挙げられる。Chromogens used in the present invention include phenol, 2-chlorophenol, 4-chlorophenol,
Phenol derivatives such as 2,4-dichlorophenol,
Or aniline, N, N-dimethylaniline, N, N
-Diethylaniline, N, N-diethyl-m-toluidine, N, N-diethyl-m-anisidine, N-ethyl-
N- (3-methylphenyl) -N'-acetylethylenediamine, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-anisidine, N-ethyl-N-
Examples thereof include aniline derivatives such as (2-hydroxy-3-sulfopropyl) -m-toluidine, N-ethyl-N-sulfopropyl-m-toluidine and N-ethyl-N-sulfopropyl-m-anisidine.
【0018】本発明に使用するアスコルビン酸オキシダ
ーゼとしては、カボチャ、キュウリなどのウリ科植物か
ら得られたもの、微生物由来のもの、遺伝子組換えによ
り製造されたもの、これらの酵素が化学修飾されたもの
などを挙げることができる。The ascorbate oxidase used in the present invention is obtained from plants of the Cucurbitaceae family such as pumpkin and cucumber, derived from microorganisms, produced by gene recombination, and these enzymes are chemically modified. You can list things such as things.
【0019】また使用する有機酸のマンガン塩として
は、酢酸マンガン、乳酸マンガン、エチレンジアミン四
酢酸マンガンなどが挙げられる。無機酸のマンガン塩と
しては、塩化マンガン、臭化マンガン、リン酸マンガ
ン、硼酸マンガン、炭酸マンガンなどが挙げられる。Examples of the organic acid manganese salt to be used include manganese acetate, manganese lactate, ethylenediaminetetraacetic acid manganese and the like. Examples of manganese salts of inorganic acids include manganese chloride, manganese bromide, manganese phosphate, manganese borate, manganese carbonate and the like.
【0020】本発明の生体成分測定用試薬組成物は、酸
化酵素、ペルオキシダーゼ、色原体、カプラー、アスコ
ルビン酸オキシダーゼおよび有機酸または無機酸のマン
ガン塩を含むものである。該組成物は測定対象である成
分によっては、酸化酵素の基質となる物質を生成する酵
素などを含む。該組成物の形状としては、液状試薬であ
っても、凍結乾燥製剤であってもよく、溶解液を組み合
わせてもよい。液状試薬には適当な緩衝剤が含まれ、一
液でも二液でもよい。The reagent composition for measuring biological components of the present invention comprises an oxidase, a peroxidase, a chromogen, a coupler, an ascorbate oxidase and a manganese salt of an organic acid or an inorganic acid. The composition contains an enzyme that produces a substance that serves as a substrate for an oxidase, depending on the component to be measured. The composition may be in the form of a liquid reagent, a freeze-dried preparation, or a combination of solutions. The liquid reagent contains an appropriate buffer, and may be one or two liquids.
【0021】試薬組成物中のアスコルビン酸オキシダー
ゼの含有量は特に限定されるものではないが、好適には
試薬組成物中、0.1〜50単位(U)/mlである。
有機酸または無機酸のマンガン塩の含有量は、試薬組成
物中、0.01〜1mMであることが好ましい。マンガ
ン塩の含有量が1mMを越えると、ブランク発色が大き
くなる傾向にあり、それに伴い測定の精密性に問題が生
じる。またマンガン塩が0.01mM未満であると、ア
スコルビン酸の影響を回避する効果は十分でない。試薬
組成物が二液である場合、アスコルビン酸オキシダーゼ
は第1試薬に存在することが好ましく、有機酸または無
機酸のマンガン塩は、第1試薬または第2試薬のいずれ
に存在してもよい。酸化酵素、酸化酵素の基質となる物
質を生成する酵素、ペルオキシダーゼ、色原体、カプラ
ーの添加量は測定に支障を来さない限り特に限定される
ものではない。The content of ascorbate oxidase in the reagent composition is not particularly limited, but it is preferably 0.1 to 50 units (U) / ml in the reagent composition.
The content of the manganese salt of an organic acid or an inorganic acid is preferably 0.01 to 1 mM in the reagent composition. When the content of manganese salt exceeds 1 mM, blank color development tends to increase, which causes a problem in measurement precision. If the manganese salt content is less than 0.01 mM, the effect of avoiding the influence of ascorbic acid is not sufficient. When the reagent composition is a two-part reagent, ascorbate oxidase is preferably present in the first reagent, and the manganese salt of an organic acid or an inorganic acid may be present in either the first reagent or the second reagent. The amount of the oxidase, the enzyme that produces a substance that serves as a substrate for the oxidase, the peroxidase, the chromogen, and the coupler is not particularly limited as long as it does not interfere with the measurement.
【0022】本発明の測定方法では、生体試料に上記試
薬組成物を作用させ、生体成分中の妨害物質を除去する
と同時、または除去して後、酸化酵素が生成する過酸化
水素にペルオキシダーゼ、色原体、カプラーが作用して
生成する色素の吸光度を測定することによって、生体試
料中の生体成分を測定する。したがってアスコルビン酸
オキシダーゼおよび有機酸または無機酸のマンガン塩を
作用させて、生体成分中の妨害物質を除去する操作は、
試料中の生体成分または該生体成分に由来する物質に酸
化酵素を作用させる操作、生成した過酸化水素を測定す
る操作のいずれにおいて実施してもよい。In the measuring method of the present invention, the above-mentioned reagent composition is allowed to act on a biological sample, and at the same time as or after the interfering substances in the biological components are removed, hydrogen peroxide produced by an oxidase is converted into peroxidase and a color. The biological components in the biological sample are measured by measuring the absorbance of the dye formed by the action of the drug substance and the coupler. Therefore, the operation to act ascorbic acid oxidase and manganese salt of organic acid or inorganic acid to remove interfering substances in biological components is
It may be carried out in any of an operation of causing an oxidase to act on a biological component in a sample or a substance derived from the biological component, and an operation of measuring the produced hydrogen peroxide.
【0023】[0023]
【発明の効果】本発明によれば、生体試料中に含まれる
アスコルビン酸が及ぼす生体成分の測定への影響を、試
料の前処理をすることなく、回避することが可能とな
る。アスコルビン酸オキシダーゼと他の金属塩、例えば
銅塩または亜鉛塩などを組み合わせても、同様の効果は
得られない。またアスコルビン酸のみの添加に比べて、
高濃度までアスコルビン酸が及ぼす生体成分の測定への
影響を回避することが可能である。また安定化剤を含有
するアスコルビン酸オキシダーゼを使用する場合に比べ
ても、高濃度までアスコルビン酸が及ぼす生体成分への
測定への影響を回避することができる。また本発明によ
る効果はアスコルビン酸の測定値に及ぼす干渉を回避す
ることにあり、アスコルビン酸オキシダーゼの安定化に
ついては顕著な効果を奏するものではない。According to the present invention, it is possible to avoid the influence of ascorbic acid contained in a biological sample on the measurement of biological components, without pretreatment of the sample. Similar effects cannot be obtained by combining ascorbate oxidase with other metal salts such as copper salts or zinc salts. Also, compared to the addition of ascorbic acid alone,
It is possible to avoid the influence of ascorbic acid up to high concentrations on the measurement of biological components. Further, even when ascorbic acid oxidase containing a stabilizer is used, it is possible to avoid the influence of ascorbic acid on biological components up to high concentrations on the measurement of biological components. Further, the effect of the present invention is to avoid interference with the measured value of ascorbic acid, and does not exert a remarkable effect on the stabilization of ascorbate oxidase.
【0024】[0024]
【実施例】以下、本発明を実施例をもって詳細に説明す
る。なお、実施例中、略号は以下のものを示す。 TOOS:N−エチル−N−(2−ヒドロキシ−3−ス
ルホプロピル)−3,5−ジメチルアニリン ATP:アデノシン三リン酸 TES:N−トリス(ヒドロキシメチル)メチル−2−
アミノエタンスルホン酸 TAPS:N−トリス(ヒドロキシメチル)メチル−3
−アミノプロパンスルホン酸 EDTA・Zn:エチレンジアミン四酢酸二ナトリウム
・亜鉛 EDTA・Cu:エチレンジアミン四酢酸二ナトリウム
・銅 EDTA・Mn:エチレンジアミン四酢酸二ナトリウム
・マンガンEXAMPLES The present invention will be described in detail below with reference to examples. In the examples, abbreviations indicate the following. TOOS: N-ethyl-N- (2-hydroxy-3-sulfopropyl) -3,5-dimethylaniline ATP: adenosine triphosphate TES: N-tris (hydroxymethyl) methyl-2-
Aminoethanesulfonic acid TAPS: N-tris (hydroxymethyl) methyl-3
-Aminopropanesulfonic acid EDTA / Zn: disodium ethylenediaminetetraacetate / zinc EDTA / Cu: disodium ethylenediaminetetraacetate / copper EDTA / Mn: disodium ethylenediaminetetraacetate / manganese
【0025】実施例1 血清中の遊離コレステロールの
測定 下記試薬A〜Cを調製した。 試薬A: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM (第2試薬) コレステロールオキシダーゼ 1.5u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM 試薬B: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) (第2試薬) コレステロールオキシダーゼ 1.5u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM 試薬C: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) 塩化マンガン 0.2mM (第2試薬) コレステロールオキシダーゼ 1.5u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mMExample 1 Measurement of Free Cholesterol in Serum The following reagents A to C were prepared. Reagent A: (First reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM (Second reagent) Cholesterol oxidase 1.5u / ml 4-Aminoantipyrine 0.6mM phosphate buffer 100mM Reagent B: (No. 1 reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM Ascorbate oxidase 0.2U / ml (from pumpkin) (2nd reagent) Cholesterol oxidase 1.5u / ml 4-aminoantipyrine 0.6mM phosphate buffer Liquid 100 mM Reagent C: (first reagent) Peroxidase 10 u / ml TOOS 2.0 mM Phosphate buffer 100 mM Ascorbate oxidase 0.2 U / ml (from pumpkin) Manganese chloride 0.2 mM (second reagent) Cholesterol Oxidase 1.5 U / ml 4-aminoantipyrine 0.6mM phosphate buffer 100mM
【0026】サンプルとしては下記サンプル1〜6を用
意した。 サンプル1 人プール血清:蒸留水=9:1 サンプル2 人プール血清: 200mg/dlアスコルビン酸
水溶液=9:1 サンプル3 人プール血清: 400mg/dlアスコルビン酸
水溶液=9:1 サンプル4 人プール血清: 600mg/dlアスコルビン酸
水溶液=9:1 サンプル5 人プール血清: 800mg/dlアスコルビン酸
水溶液=9:1 サンプル6 人プール血清:1000mg/dlアスコルビン酸
水溶液=9:1The following samples 1 to 6 were prepared as samples. Sample 1 person pool serum: distilled water = 9: 1 sample 2 person pool serum: 200 mg / dl ascorbic acid aqueous solution = 9: 1 sample 3 person pool serum: 400 mg / dl ascorbic acid aqueous solution = 9: 1 sample 4 person pool serum: 600 mg / dl ascorbic acid aqueous solution = 9: 1 sample 5 person pool serum: 800 mg / dl ascorbic acid aqueous solution = 9: 1 sample 6 person pool serum: 1000 mg / dl ascorbic acid aqueous solution = 9: 1
【0027】各サンプル4μlに各試薬A〜Cの第1試
薬を200μl添加し、37℃で5分間加温後、試薬A
〜Cの第2試薬を100μl添加し、37℃で5分間加
温後、精製水を対照に546nmの吸光度を測定した。得
られた吸光度をもとに、あらかじめ標準液を用いて作成
した検量線から遊離コレステロール濃度を求めた。その
結果を表2に示す。表中、数字は単位 mg/dlを示す。To 4 μl of each sample, 200 μl of the first reagent of each of the reagents A to C was added, and after heating at 37 ° C. for 5 minutes, the reagent A was added.
After adding 100 μl of the second reagent of -C and heating at 37 ° C. for 5 minutes, the absorbance at 546 nm was measured using purified water as a control. Based on the obtained absorbance, the free cholesterol concentration was determined from a calibration curve prepared in advance using a standard solution. The results are shown in Table 2. In the table, the numbers indicate the unit mg / dl.
【0028】[0028]
【表2】 [Table 2]
【0029】表1から明らかなように、試薬Aではアス
コルビン酸の影響を受けて遊離コレステロールを正確に
測定できない。またアスコルビン酸オキシダーゼのみを
作用させる試薬Bではアスコルビン酸濃度が高いサンプ
ルではアスコルビン酸の影響を受ける。しかし本発明の
試薬Cではアスコルビン酸濃度が高いサンプルでもその
影響を回避することできる。As is apparent from Table 1, the reagent A cannot be accurately measured for free cholesterol due to the influence of ascorbic acid. Further, the reagent B that acts only ascorbic acid oxidase is affected by ascorbic acid in a sample having a high ascorbic acid concentration. However, with the reagent C of the present invention, the influence can be avoided even in a sample having a high ascorbic acid concentration.
【0030】実施例2 血清中の尿酸の測定 下記試薬D〜Fを調製した。 試薬D: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM 試薬E: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.2u/ml (カボチャ由来) (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM 試薬F: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) 塩化マンガン 0.2mM (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM サンプルとしては実施例1と同じサンプル1〜6を用意
した。Example 2 Measurement of Uric Acid in Serum The following reagents D to F were prepared. Reagent D: (1st reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM (2nd reagent) Uricase 1u / ml 4-aminoantipyrine 0.6mM phosphate buffer 100mM Reagent E: (1st reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM Ascorbate oxidase 0.2u / ml (from pumpkin) (2nd reagent) Uricase 1u / ml 4-aminoantipyrine 0.6mM phosphate buffer 100mM reagent F: ( 1st reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM Ascorbate oxidase 0.2U / ml (from pumpkin) Manganese chloride 0.2mM (2nd reagent) Uricase 1u / ml 4-aminoantipyrine 0.6m The phosphate buffer 100mM sample was prepared the same sample 1-6 of Example 1.
【0031】各サンプル6μlに各試薬D〜Fの第1試
薬を200μl添加し、37℃で5分間加温後、各試薬
D〜Fの第2試薬を100μl添加し、37℃で5分間
加温後、精製水を対照に546nmの吸光度を測定した。
得られた吸光度をもとに、あらかじめ標準液を用いて作
成した検量線から尿酸濃度を求めた。その結果を表3に
示す。表中、数字は単位 mg/dlを示す。To 6 μl of each sample, 200 μl of the first reagent of each of reagents D to F was added, and after heating at 37 ° C. for 5 minutes, 100 μl of the second reagent of each of reagents D to F was added, and then added at 37 ° C. for 5 minutes. After warming, the absorbance at 546 nm was measured using purified water as a control.
Based on the obtained absorbance, the uric acid concentration was determined from a calibration curve prepared in advance using a standard solution. The results are shown in Table 3. In the table, the numbers indicate the unit mg / dl.
【0032】[0032]
【表3】 [Table 3]
【0033】表2から明らかなように、アスコルビン酸
濃度が高いサンプルにおいても、本発明の試薬Fは妨害
物質の影響を回避することできる。As is clear from Table 2, the reagent F of the present invention can avoid the influence of interfering substances even in a sample having a high ascorbic acid concentration.
【0034】実施例3 中性脂肪の測定 下記試薬G〜Iを調製した。 試薬G: (第1試薬) グリセロールキナーゼ 1u/ml グリセロール−3−リン酸オキシダーゼ 5u/ml ペルオキシダーゼ 10u/ml TOOS 2mM ATP 3mM TES緩衝液 50mM (第2試薬) リポプロテインリパーゼ 3u/ml 4−アミノアンチピリン 0.6mM TES緩衝液 50mM 試薬H: (第1試薬) グリセロールキナーゼ 1u/ml グリセロール−3−リン酸オキシダーゼ 5u/ml ペルオキシダーゼ 10u/ml TOOS 2mM ATP 3mM TES緩衝液 50mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) (第2試薬) リポプロテインリパーゼ 3u/ml 4−アミノアンチピリン 0.6mM TES緩衝液 50mMExample 3 Measurement of Neutral Fat The following reagents G to I were prepared. Reagent G: (First reagent) Glycerol kinase 1 u / ml Glycerol-3-phosphate oxidase 5 u / ml Peroxidase 10 u / ml TOOS 2 mM ATP 3 mM TES buffer 50 mM (Second reagent) Lipoprotein lipase 3 u / ml 4-aminoantipyrine 0.6 mM TES buffer 50 mM Reagent H: (first reagent) Glycerol kinase 1 u / ml Glycerol-3-phosphate oxidase 5 u / ml Peroxidase 10 u / ml TOOS 2 mM ATP 3 mM TES buffer 50 mM Ascorbate oxidase 0.2 U / ml (From pumpkin) (2nd reagent) lipoprotein lipase 3u / ml 4-aminoantipyrine 0.6mM TES buffer 50mM
【0035】 試薬I: (第1試薬) グリセロールキナーゼ 1u/ml グリセロール−3−リン酸オキシダーゼ 5u/ml ペルオキシダーゼ 10u/ml TOOS 2mM ATP 3mM TES緩衝液 50mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) 塩化マンガン 0.2mM (第2試薬) リポプロテインリパーゼ 3u/ml 4−アミノアンチピリン 0.6mM TES緩衝液 50mM サンプルとしては実施例1と同じサンプル1〜6を用意
した。Reagent I: (First reagent) Glycerol kinase 1 u / ml Glycerol-3-phosphate oxidase 5 u / ml Peroxidase 10 u / ml TOOS 2 mM ATP 3 mM TES buffer 50 mM Ascorbate oxidase 0.2 U / ml (from pumpkin) Manganese chloride 0.2 mM (second reagent) Lipoprotein lipase 3 u / ml 4-aminoantipyrine 0.6 mM TES buffer 50 mM As samples, the same samples 1 to 6 as in Example 1 were prepared.
【0036】各サンプル3μlに試薬G〜Iの第1試薬
を250μl添加し、37℃で5分間加温後、試薬G〜
Iの第2試薬を125μl添加し、37℃で5分間加温
後、精製水を対照に546nmの吸光度を測定した。得ら
れた吸光度をもとにあらかじめ標準液を用いて作成した
検量線から中性脂肪濃度を求めた。その結果を表4に示
す。表中の数値は単位 mg/dlを示す。250 μl of the first reagent of reagents G to I was added to 3 μl of each sample and heated at 37 ° C. for 5 minutes.
After adding 125 μl of the second reagent of I and heating at 37 ° C. for 5 minutes, the absorbance at 546 nm was measured using purified water as a control. Based on the obtained absorbance, the neutral fat concentration was determined from a calibration curve prepared in advance using a standard solution. The results are shown in Table 4. Numerical values in the table indicate the unit mg / dl.
【0037】[0037]
【表4】 [Table 4]
【0038】表3から明らかなように、アスコルビン酸
濃度が高いサンプルにおいても、本発明の試薬Iは妨害
物質の影響を回避することできる。As is clear from Table 3, the reagent I of the present invention can avoid the influence of interfering substances even in a sample having a high ascorbic acid concentration.
【0039】実施例4 血清リン脂質の測定 下記試薬J〜Lを調製した。 試薬J: (第1試薬) ホスフォリパーゼD 0.5u/ml ペルオキシダーゼ 10u/ml TOOS 2mM トリス緩衝液 50mM (第2試薬) コリンオキシダーゼ 10u/ml 4−アミノアンチピリン 0.6mM トリス緩衝液 50mMExample 4 Measurement of Serum Phospholipid The following reagents J to L were prepared. Reagent J: (First reagent) Phospholipase D 0.5u / ml Peroxidase 10u / ml TOOS 2mM Tris buffer 50mM (Second reagent) Choline oxidase 10u / ml 4-Aminoantipyrine 0.6mM Tris buffer 50mM
【0040】 試薬K: (第1試薬) ホスフォリパーゼD 0.5u/ml ペルオキシダーゼ 10u/ml TOOS 2mM トリス緩衝液 50mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) (第2試薬) コリンオキシダーゼ 10u/ml 4−アミノアンチピリン 0.6mM トリス緩衝液 50mM 試薬L: (第1試薬) ホスフォリパーゼD 0.5u/ml ペルオキシダーゼ 10u/ml TOOS 2mM トリス緩衝液 50mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) 塩化マンガン 0.2mM (第2試薬) コリンオキシダーゼ 10u/ml 4−アミノアンチピリン 0.6mM トリス緩衝液 50mM サンプルとしては実施例1と同じサンプル1〜6を用意
した。Reagent K: (First reagent) Phospholipase D 0.5u / ml Peroxidase 10u / ml TOOS 2mM Tris buffer 50mM Ascorbate oxidase 0.2U / ml (from pumpkin) (Second reagent) Choline oxidase 10u / Ml 4-aminoantipyrine 0.6 mM Tris buffer 50 mM Reagent L: (first reagent) Phospholipase D 0.5 u / ml peroxidase 10 u / ml TOOS 2 mM Tris buffer 50 mM ascorbate oxidase 0.2 U / ml (pumpkin Origin) Manganese chloride 0.2 mM (second reagent) Choline oxidase 10 u / ml 4-aminoantipyrine 0.6 mM Tris buffer 50 mM As samples, the same samples 1 to 6 as in Example 1 were prepared.
【0041】各サンプル3μlに試薬J〜Lの第1試薬
を250μl添加し、37℃で5分間加温後、試薬J〜
Lの第2試薬を125μl添加し、37℃で5分間加温
後、精製水を対照に546nmの吸光度を測定した。得ら
れた吸光度をもとにあらかじめ標準液を用いて作成した
検量線からリン脂質濃度を求めた。その結果を表5に示
す。表中の数値は単位 mg/dlを示す。250 μl of the first reagent of reagents J to L was added to 3 μl of each sample, and after heating at 37 ° C. for 5 minutes, the reagents J to L
After adding 125 μl of L of the second reagent and heating at 37 ° C. for 5 minutes, the absorbance at 546 nm was measured using purified water as a control. Based on the obtained absorbance, the phospholipid concentration was determined from a calibration curve prepared in advance using a standard solution. The results are shown in Table 5. Numerical values in the table indicate the unit mg / dl.
【0042】[0042]
【表5】 [Table 5]
【0043】表4から明らかなように、アスコルビン酸
濃度が高いサンプルにおいても、本発明の試薬Lは妨害
物質の影響を回避することできる。As is clear from Table 4, the reagent L of the present invention can avoid the influence of interfering substances even in a sample having a high ascorbic acid concentration.
【0044】実施例5 血清クレアチニンの測定 下記試薬M〜Oを調製した。 試薬M: (第1試薬) クレアチンアミジノヒドロラーゼ 100u/ml ザルコシンオキシダーゼ 10u/ml ペルオキシダーゼ 10u/ml TOOS 2mM TAPS緩衝液 50mM (第2試薬) クレアチニンアミドヒドロラーゼ 300u/ml 4−アミノアンチピリン 0.6mM TAPS緩衝液 50mM 試薬N: (第1試薬) クレアチンアミジノヒドロラーゼ 100u/ml ザルコシンオキシダーゼ 10u/ml ペルオキシダーゼ 10u/ml TOOS 2mM TAPS緩衝液 50mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) (第2試薬) クレアチニンアミドヒドロラーゼ 300u/ml 4−アミノアンチピリン 0.6mM TAPS緩衝液 50mMExample 5 Measurement of serum creatinine The following reagents M to O were prepared. Reagent M: (first reagent) creatine amidinohydrolase 100u / ml sarcosine oxidase 10u / ml peroxidase 10u / ml TOOS 2mM TAPS buffer 50mM (second reagent) creatinine amide hydrolase 300u / ml 4-aminoantipyrine 0.6mM TAPS buffer Liquid 50 mM Reagent N: (first reagent) Creatine amidinohydrolase 100 u / ml sarcosine oxidase 10 u / ml peroxidase 10 u / ml TOOS 2 mM TAPS buffer 50 mM ascorbate oxidase 0.2 U / ml (from pumpkin) (second reagent) creatinine Amidohydrolase 300u / ml 4-aminoantipyrine 0.6mM TAPS buffer 50mM
【0045】 試薬O: (第1試薬) クレアチンアミジノヒドロラーゼ 100u/ml ザルコシンオキシダーゼ 10u/ml ペルオキシダーゼ 10u/ml TOOS 2mM TAPS緩衝液 50mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) 塩化マンガン 0.2mM (第2試薬) クレアチニンアミドヒドロラーゼ 300u/ml 4−アミノアンチピリン 0.6mM TAPS緩衝液 50mM サンプルとしては実施例1と同じサンプル1〜6を用意
した。Reagent O: (first reagent) creatine amidinohydrolase 100u / ml sarcosine oxidase 10u / ml peroxidase 10u / ml TOOS 2mM TAPS buffer 50mM ascorbate oxidase 0.2U / ml (from pumpkin) manganese chloride 0.2mM (Second reagent) Creatinine amide hydrolase 300 u / ml 4-aminoantipyrine 0.6 mM TAPS buffer 50 mM As samples, the same samples 1 to 6 as in Example 1 were prepared.
【0046】各サンプル6μlに試薬M〜Oの第1試薬
を300μl添加し、37℃で5分間加温後、試薬M〜
Oの第2試薬を100μl添加し、37℃で5分間加温
後、精製水を対照に546nmの吸光度を測定した。得ら
れた吸光度をもとにあらかじめ標準液を用いて作成した
検量線からクレアチニン濃度を求めた。その結果を表6
に示す。表中、数値は単位 mg/dlを示す。To 6 μl of each sample, 300 μl of the first reagent of reagents M to O was added, and after heating at 37 ° C. for 5 minutes, the reagents M to O were added.
After adding 100 μl of the second reagent of O and heating at 37 ° C. for 5 minutes, the absorbance at 546 nm was measured using purified water as a control. The creatinine concentration was determined from a calibration curve prepared in advance using a standard solution based on the obtained absorbance. The results are shown in Table 6
Shown in. In the table, the numerical values indicate the unit mg / dl.
【0047】[0047]
【表6】 [Table 6]
【0048】表5から明らかなように、アスコルビン酸
濃度が高いサンプルにおいても、本発明の試薬Oは妨害
物質の影響を回避することできる。As is clear from Table 5, the reagent O of the present invention can avoid the influence of interfering substances even in a sample having a high ascorbic acid concentration.
【0049】実施例6 血清尿酸の測定 下記試薬P〜Sを調製した。 試薬P: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM 試薬Q: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) EDTA・Zn 0.2mM (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mMExample 6 Measurement of serum uric acid The following reagents P to S were prepared. Reagent P: (1st reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM (2nd reagent) Uricase 1u / ml 4-aminoantipyrine 0.6mM phosphate buffer 100mM Reagent Q: (1st reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM Ascorbate oxidase 0.2U / ml (from pumpkin) EDTA.Zn 0.2mM (second reagent) Uricase 1u / ml 4-aminoantipyrine 0.6mM phosphate buffer Liquid 100 mM
【0050】試薬R: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) EDTA・Cu 0.2mM (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM 試薬S: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.2U/ml (カボチャ由来) EDTA・Mn 0.2mM (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM サンプルとしては実施例1と同じサンプル1〜6を用意
した。Reagent R: (First reagent) Peroxidase 10 u / ml TOOS 2.0 mM Phosphate buffer 100 mM Ascorbate oxidase 0.2 U / ml (from pumpkin) EDTA / Cu 0.2 mM (second reagent) Uricase 1 u / ml 4-Aminoantipyrine 0.6 mM Phosphate buffer 100 mM Reagent S: (First reagent) Peroxidase 10 u / ml TOOS 2.0 mM Phosphate buffer 100 mM Ascorbate oxidase 0.2 U / ml (from pumpkin) EDTA Mn 0 .2 mM (second reagent) uricase 1 u / ml 4-aminoantipyrine 0.6 mM phosphate buffer 100 mM As samples, the same samples 1 to 6 as in Example 1 were prepared.
【0051】各サンプル6μlに各試薬P〜Sの第1試
薬試薬を200μl添加し、37℃で5分間加温後、各
試薬P〜Sの第2試薬を100μl添加し、37℃で5
分間加温後、精製水を対照に546nmの吸光度を測定し
た。得られた吸光度をもとに、あらかじめ標準液を用い
て作成した検量線から尿酸濃度を求めた。その結果を表
7に示す。表中、数字は単位 mg/dlを示す。To 6 μl of each sample, 200 μl of the first reagent of each of the reagents P to S was added, and after heating at 37 ° C. for 5 minutes, 100 μl of the second reagent of each of the reagents P to S was added, followed by addition of 5 μl at 37 ° C.
After warming for minutes, the absorbance at 546 nm was measured using purified water as a control. Based on the obtained absorbance, the uric acid concentration was determined from a calibration curve prepared in advance using a standard solution. The results are shown in Table 7. In the table, the numbers indicate the unit mg / dl.
【0052】[0052]
【表7】 [Table 7]
【0053】表6から明らかなように、アスコルビン酸
濃度が高いサンプルにおいても、EDTA・Mnを含む
本発明の試薬Sはその影響を回避することができる。As is clear from Table 6, the influence of the reagent S of the present invention containing EDTA.Mn can be avoided even in a sample having a high ascorbic acid concentration.
【0054】実施例7 血清尿酸の測定 下記試薬T〜Vを調製した。 試薬T: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mMExample 7 Measurement of Serum Uric Acid The following reagents T to V were prepared. Reagent T: (First reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM (Second reagent) Uricase 1u / ml 4-aminoantipyrine 0.6mM phosphate buffer 100mM
【0055】試薬U: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.5u/ml (カボチャ由来) (第2試薬) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM 試薬V: (第1試薬) ペルオキシダーゼ 10u/ml TOOS 2.0mM リン酸緩衝液 100mM アスコルビン酸オキシダーゼ 0.5u/ml (カボチャ由来) 塩化マンガン 0.2mM (試薬2) ウリカーゼ 1u/ml 4−アミノアンチピリン 0.6mM リン酸緩衝液 100mM サンプルとしては実施例1と同じサンプル1〜6を用意
した。Reagent U: (First reagent) Peroxidase 10u / ml TOOS 2.0mM phosphate buffer 100mM Ascorbate oxidase 0.5u / ml (from pumpkin) (Second reagent) Uricase 1u / ml 4-aminoantipyrine 0 6 mM phosphate buffer 100 mM reagent V: (first reagent) peroxidase 10 u / ml TOOS 2.0 mM phosphate buffer 100 mM ascorbate oxidase 0.5 u / ml (from pumpkin) manganese chloride 0.2 mM (reagent 2) uricase 1 u / ml 4-aminoantipyrine 0.6 mM phosphate buffer 100 mM As samples, the same samples 1 to 6 as in Example 1 were prepared.
【0056】サンプル6μlに各試薬T〜Vの第1試薬
を200μl添加し、37℃で5分間加温後、各試薬T
〜Vの第2試薬を100μl添加し、37℃で5分間加
温後、精製水を対照に546nmの吸光度を測定した。得
られた吸光度をもとに、あらかじめ標準液を用いて作成
した検量線から尿酸濃度を求めた。同様にして調製した
各試薬U〜Vを37℃で3日間保存後、測定を行なっ
た。その結果を表8に示す。表中、数字は単位 mg/dlを
示す。200 μl of the first reagent of each reagent T to V was added to 6 μl of the sample, and after heating at 37 ° C. for 5 minutes, each reagent T
After adding 100 μl of the second reagent of -V and heating at 37 ° C for 5 minutes, the absorbance at 546 nm was measured using purified water as a control. Based on the obtained absorbance, the uric acid concentration was determined from a calibration curve prepared in advance using a standard solution. Each of the reagents U to V prepared in the same manner was stored at 37 ° C. for 3 days and then measured. The results are shown in Table 8. In the table, the numbers indicate the unit mg / dl.
【0057】[0057]
【表8】 [Table 8]
【0058】表7から明らかなように、アスコルビン酸
濃度が高いサンプルにおいても、本発明の試薬Vはその
影響を回避することができる。また37℃で3日間保存
した試薬については、よりその効果が顕著である。As is clear from Table 7, the effect of the reagent V of the present invention can be avoided even in a sample having a high ascorbic acid concentration. Further, the effect is more remarkable for the reagent stored at 37 ° C. for 3 days.
Claims (14)
来する物質に酸化酵素を作用させ、生成した過酸化水素
を測定することにより生体成分を測定する方法におい
て、アスコルビン酸オキシダーゼおよび有機酸または無
機酸のマンガン塩を作用させて、生体成分中の妨害物質
を除去することを特徴とする生体成分の測定方法。1. A method for measuring a biological component by causing an oxidase to act on a biological component or a substance derived from the biological component in a sample and measuring the produced hydrogen peroxide, wherein ascorbic acid oxidase and an organic acid or A method for measuring a biological component, which comprises reacting a manganese salt of an inorganic acid to remove interfering substances in the biological component.
ゼ、色原体およびカプラーを用いて定量することを特徴
とする請求項1項記載の生体成分の測定方法。2. The method for measuring a biological component according to claim 1, wherein the produced hydrogen peroxide is quantified using a peroxidase, a chromogen and a coupler.
酸マンガン、乳酸マンガン、エチレンジアミン四酢酸マ
ンガン、塩化マンガン、臭化マンガン、リン酸マンガ
ン、硼酸マンガンまたは炭酸マンガンであることを特徴
とする請求項1記載の生体成分の測定方法。3. The manganese salt of an organic acid or an inorganic acid is manganese acetate, manganese lactate, ethylenediamine tetraacetate manganese, manganese chloride, manganese bromide, manganese phosphate, manganese borate or manganese carbonate. Item 1. A method for measuring a biological component according to item 1.
量が、試薬組成物中、0.01〜1mMであることを特
徴とする請求項1項記載の生体成分の測定方法。4. The method for measuring a biological component according to claim 1, wherein the content of the manganese salt of an organic acid or an inorganic acid is 0.01 to 1 mM in the reagent composition.
ール、エステル型コレステロール、中性脂肪、リン脂
質、無機リン、クレアチン、クレアチニン、遊離脂肪
酸、尿素窒素、ピルビン酸または尿酸であることを特徴
とする請求項1記載の生体成分の測定方法。5. The biological component is glucose, free cholesterol, ester cholesterol, neutral fat, phospholipid, inorganic phosphorus, creatine, creatinine, free fatty acid, urea nitrogen, pyruvic acid or uric acid. 1. The method for measuring a biological component according to 1.
カプラー、アスコルビン酸オキシダーゼおよび有機酸ま
たは無機酸のマンガン塩を含むことを特徴とする生体成
分の測定用試薬組成物。6. An oxidase, a peroxidase, a chromogen,
A reagent composition for measuring a biological component, which comprises a coupler, ascorbate oxidase, and a manganese salt of an organic acid or an inorganic acid.
酵素、酸化酵素、ペルオキシダーゼ、色原体、カプラ
ー、アスコルビン酸オキシダーゼおよび有機酸または無
機酸のマンガン塩を含むことを特徴とする生体成分の測
定用試薬組成物。7. A biocomponent comprising an enzyme that produces a substrate for an oxidase from the biocomponent, an oxidase, a peroxidase, a chromogen, a coupler, an ascorbate oxidase, and a manganese salt of an organic acid or an inorganic acid. Measuring reagent composition.
酸マンガン、乳酸マンガン、エチレンジアミン四酢酸マ
ンガン、塩化マンガン、臭化マンガン、リン酸マンガ
ン、硼酸マンガンまたは炭酸マンガンであることを特徴
とする請求項6または7記載の生体成分の測定用試薬組
成物。8. The manganese salt of an organic acid or an inorganic acid is manganese acetate, manganese lactate, ethylenediaminetetraacetate manganese, manganese chloride, manganese bromide, manganese phosphate, manganese borate or manganese carbonate. Item 6. A reagent composition for measuring a biological component according to item 6 or 7.
量が、試薬組成物中、0.01〜1mMであることを特
徴とする請求項6または7項記載の生体成分の測定用試
薬組成物。9. The reagent composition for measuring a biological component according to claim 6, wherein the content of the manganese salt of an organic acid or an inorganic acid is 0.01 to 1 mM in the reagent composition. object.
ロール、ピルビン酸または尿酸であることを特徴とする
請求項6記載の生体成分の測定用試薬組成物。10. The reagent composition for measuring a biological component according to claim 6, wherein the biological component is glucose, free cholesterol, pyruvic acid or uric acid.
コレステロールオキシダーゼ、ピルビン酸オキシダーゼ
またはウリカーゼであることを特徴とする請求項6記載
の生体成分の測定用試薬組成物。11. The oxidase is glucose oxidase,
The reagent composition for measuring a biological component according to claim 6, which is cholesterol oxidase, pyruvate oxidase or uricase.
ル、中性脂肪、リン脂質、無機リン、クレアチン、クレ
アチニン、遊離脂肪酸または尿素窒素であることを特徴
とする請求項7記載の生体成分の測定用試薬組成物。12. The reagent composition for measuring a biological component according to claim 7, wherein the biological component is ester cholesterol, neutral fat, phospholipid, inorganic phosphorus, creatine, creatinine, free fatty acid or urea nitrogen. object.
る酵素が、コレステロールエステラーゼ、リポプロテイ
ンリパーゼ、グリセリンキナーゼ、ホスフォリパーゼ
D、プリンヌクレオシドホスフォリラーゼ、クレアチン
アミジノヒドロラーゼ、クレアチニンアミドヒドロラー
ゼ、アシルCoAシンセターゼまたはウレアミドリアー
ゼであることを特徴とする請求項7記載の生体成分の測
定用試薬組成物。13. An enzyme that produces a substrate for an oxidase from a biological component is cholesterol esterase, lipoprotein lipase, glycerin kinase, phospholipase D, purine nucleoside phosphorylase, creatine amidinohydrolase, creatinine amide hydrolase, acyl CoA synthetase. Alternatively, the reagent composition for measuring a biological component according to claim 7, which is ureamide lyase.
ゼ、グリセロールオキシダーゼ、グリセロール−3−リ
ン酸オキシダーゼ、コリンオキシダーゼ、キサンチンオ
キシダーゼ、ザルコシンオキシダーゼ、アシルCoAオ
キシダーゼまたはピルビン酸オキシダーゼであることを
特徴とする請求項7記載の生体成分の測定用試薬組成
物。14. The oxidase is cholesterol oxidase, glycerol oxidase, glycerol-3-phosphate oxidase, choline oxidase, xanthine oxidase, sarcosine oxidase, acyl CoA oxidase or pyruvate oxidase. Reagent composition for measuring biological components of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09998394A JP3695596B2 (en) | 1994-05-13 | 1994-05-13 | Biological component measurement method and reagent composition for measurement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09998394A JP3695596B2 (en) | 1994-05-13 | 1994-05-13 | Biological component measurement method and reagent composition for measurement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07303497A true JPH07303497A (en) | 1995-11-21 |
| JP3695596B2 JP3695596B2 (en) | 2005-09-14 |
Family
ID=14261904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09998394A Expired - Lifetime JP3695596B2 (en) | 1994-05-13 | 1994-05-13 | Biological component measurement method and reagent composition for measurement |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3695596B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019216405A1 (en) * | 2018-05-10 | 2019-11-14 | 東洋紡株式会社 | Method for suppressing reduction in sensitivity of biological-component-measuring reagent kit |
| JP2020018204A (en) * | 2018-07-31 | 2020-02-06 | 株式会社エンザイム・センサ | METHOD FOR MEASURING γ-AMINOBUTYRIC ACID, AND KIT FOR THE SAME |
| CN111999352A (en) * | 2019-05-26 | 2020-11-27 | 谢艳 | Detection method or kit for hydrogen peroxide |
| JPWO2021054432A1 (en) * | 2019-09-19 | 2021-03-25 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5633000A (en) * | 1979-08-24 | 1981-04-02 | Wako Pure Chem Ind Ltd | Elimination of positive error |
| JPS56151358A (en) * | 1980-03-29 | 1981-11-24 | Boehringer Mannheim Gmbh | Method of and diagnosing agent for detecting redox reaction |
| JPS5855757A (en) * | 1981-09-29 | 1983-04-02 | Fujirebio Inc | Method for removing reducing interfering substances |
| JPH02286099A (en) * | 1989-04-13 | 1990-11-26 | Miles Inc | Ascorbic acid interference-reducing agent at liquid phase or dry phase tester strain and method related to it |
| JPH05184392A (en) * | 1991-05-13 | 1993-07-27 | Miles Inc | Ascorbic acid salt interference resisting composition, tester and method for assay of predetermined subject |
| JPH08131197A (en) * | 1994-03-08 | 1996-05-28 | Kyowa Medex Co Ltd | Determination of cholesterol in high-density lipoprotein |
-
1994
- 1994-05-13 JP JP09998394A patent/JP3695596B2/en not_active Expired - Lifetime
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5633000A (en) * | 1979-08-24 | 1981-04-02 | Wako Pure Chem Ind Ltd | Elimination of positive error |
| JPS56151358A (en) * | 1980-03-29 | 1981-11-24 | Boehringer Mannheim Gmbh | Method of and diagnosing agent for detecting redox reaction |
| JPS5855757A (en) * | 1981-09-29 | 1983-04-02 | Fujirebio Inc | Method for removing reducing interfering substances |
| JPH02286099A (en) * | 1989-04-13 | 1990-11-26 | Miles Inc | Ascorbic acid interference-reducing agent at liquid phase or dry phase tester strain and method related to it |
| JPH05184392A (en) * | 1991-05-13 | 1993-07-27 | Miles Inc | Ascorbic acid salt interference resisting composition, tester and method for assay of predetermined subject |
| JPH08131197A (en) * | 1994-03-08 | 1996-05-28 | Kyowa Medex Co Ltd | Determination of cholesterol in high-density lipoprotein |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019216405A1 (en) * | 2018-05-10 | 2019-11-14 | 東洋紡株式会社 | Method for suppressing reduction in sensitivity of biological-component-measuring reagent kit |
| JPWO2019216405A1 (en) * | 2018-05-10 | 2021-07-01 | 東洋紡株式会社 | Method for suppressing decrease in sensitivity of biological component measurement reagent kit |
| JP2020018204A (en) * | 2018-07-31 | 2020-02-06 | 株式会社エンザイム・センサ | METHOD FOR MEASURING γ-AMINOBUTYRIC ACID, AND KIT FOR THE SAME |
| CN111999352A (en) * | 2019-05-26 | 2020-11-27 | 谢艳 | Detection method or kit for hydrogen peroxide |
| JPWO2021054432A1 (en) * | 2019-09-19 | 2021-03-25 | ||
| WO2021054432A1 (en) * | 2019-09-19 | 2021-03-25 | 積水メディカル株式会社 | Method for measuring target component using enzyme, and measurement reagent |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3695596B2 (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4543326A (en) | Stabilization of oxidase | |
| CS228127B2 (en) | Reagencni cinidlo | |
| US3977944A (en) | Enzyme-kinetic determination of the concentration of a substrate | |
| CN101061234B (en) | Composition and method for assaying lipase activity | |
| EP0116307B1 (en) | Composition, analytical element and method for the quantification of creatine kinase | |
| US5962248A (en) | Quantitative determination method for chloride ions | |
| JPS5948098A (en) | Measurement of lipase | |
| JPH07303497A (en) | Assay of biological component and reagent composition therefor | |
| JP3978622B2 (en) | Method for measuring components in body fluid and its reagent | |
| US4695539A (en) | Process for quantitative determination of substrate treated with oxidase | |
| JP4620881B2 (en) | Method for stabilizing ascorbate oxidase and reagent for measuring biological components | |
| JP4542541B2 (en) | Stabilized cholinesterase substrate solution | |
| JP4081709B2 (en) | How to avoid the effects of contaminants | |
| US5436133A (en) | Enzyme assay of biochemical substances | |
| EP0486997B1 (en) | Reagent for calcium ion level determination | |
| CA1202869A (en) | Method for the quantitative measurement of the phosphatidyl glycerol | |
| JPH0434400B2 (en) | ||
| JP3868214B2 (en) | Stabilization of liquid catalase | |
| JP3693302B2 (en) | Calcium ion measuring method and composition | |
| EP0386237A1 (en) | Enzyme assay of biological substances | |
| JP3522307B2 (en) | Liquid reagent composition for measuring inorganic phosphorus | |
| US5840512A (en) | Method for measurement of ionized calcium | |
| JP2562882B2 (en) | Stabilization method of reagents for measuring biological components | |
| WO2023190714A1 (en) | Method for measuring lysophospholipase d activity, sensitivity enhancement agent for lysophospholipase d activity measurement, composition, and kit | |
| JPH0461640B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050317 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050511 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050610 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050623 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080708 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090708 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090708 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100708 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100708 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110708 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120708 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130708 Year of fee payment: 8 |
|
| EXPY | Cancellation because of completion of term |